GENELUX CORP (GNLX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GNLX • US36870H1032

2.39 USD
+0.04 (+1.7%)
At close: Feb 6, 2026
2.34 USD
-0.05 (-2.09%)
After Hours: 2/6/2026, 8:00:01 PM
Fundamental Rating

2

Overall GNLX gets a fundamental rating of 2 out of 10. We evaluated GNLX against 523 industry peers in the Biotechnology industry. The financial health of GNLX is average, but there are quite some concerns on its profitability. GNLX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • GNLX had negative earnings in the past year.
  • GNLX had a negative operating cash flow in the past year.
  • GNLX had negative earnings in each of the past 5 years.
  • In the past 5 years GNLX always reported negative operating cash flow.
GNLX Yearly Net Income VS EBIT VS OCF VS FCFGNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -127.56%, GNLX is not doing good in the industry: 79.81% of the companies in the same industry are doing better.
  • GNLX has a Return On Equity of -171.45%. This is in the lower half of the industry: GNLX underperforms 65.90% of its industry peers.
Industry RankSector Rank
ROA -127.56%
ROE -171.45%
ROIC N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNLX Yearly ROA, ROE, ROICGNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • GNLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNLX Yearly Profit, Operating, Gross MarginsGNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K

6

2. Health

2.1 Basic Checks

  • GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GNLX has more shares outstanding
  • GNLX has more shares outstanding than it did 5 years ago.
  • GNLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNLX Yearly Shares OutstandingGNLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
GNLX Yearly Total Debt VS Total AssetsGNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -10.48, we must say that GNLX is in the distress zone and has some risk of bankruptcy.
  • GNLX has a Altman-Z score of -10.48. This is in the lower half of the industry: GNLX underperforms 72.57% of its industry peers.
  • GNLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.48
ROIC/WACCN/A
WACC8.86%
GNLX Yearly LT Debt VS Equity VS FCFGNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 4.20 indicates that GNLX has no problem at all paying its short term obligations.
  • With a Current ratio value of 4.20, GNLX perfoms like the industry average, outperforming 50.10% of the companies in the same industry.
  • A Quick Ratio of 4.20 indicates that GNLX has no problem at all paying its short term obligations.
  • GNLX has a Quick ratio (4.20) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 4.2
GNLX Yearly Current Assets VS Current LiabilitesGNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

3

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.37% over the past year.
  • Looking at the last year, GNLX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)7.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, GNLX will show a very strong growth in Earnings Per Share. The EPS will grow by 23.58% on average per year.
  • Based on estimates for the next years, GNLX will show a very strong growth in Revenue. The Revenue will grow by 730.34% on average per year.
EPS Next Y9.9%
EPS Next 2Y-0.78%
EPS Next 3Y0.04%
EPS Next 5Y23.58%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1828.68%
Revenue Next 5Y730.34%

3.3 Evolution

GNLX Yearly Revenue VS EstimatesGNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M
GNLX Yearly EPS VS EstimatesGNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

0

4. Valuation

4.1 Price/Earnings Ratio

  • GNLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNLX Price Earnings VS Forward Price EarningsGNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNLX Per share dataGNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.78%
EPS Next 3Y0.04%

0

5. Dividend

5.1 Amount

  • No dividends for GNLX!.
Industry RankSector Rank
Dividend Yield 0%

GENELUX CORP

NASDAQ:GNLX (2/6/2026, 8:00:01 PM)

After market: 2.34 -0.05 (-2.09%)

2.39

+0.04 (+1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-09
Inst Owners30.77%
Inst Owner Change3.69%
Ins Owners12.8%
Ins Owner Change35.88%
Market Cap90.94M
Revenue(TTM)N/A
Net Income(TTM)-31.87M
Analysts81.67
Price Target19.72 (725.1%)
Short Float %9.23%
Short Ratio12.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.84%
Min EPS beat(2)2.89%
Max EPS beat(2)8.8%
EPS beat(4)3
Avg EPS beat(4)-3.22%
Min EPS beat(4)-39.67%
Max EPS beat(4)15.1%
EPS beat(8)4
Avg EPS beat(8)-9.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.77%
EPS NY rev (1m)0%
EPS NY rev (3m)2.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.89
P/tB 4.89
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -127.56%
ROE -171.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 315.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 4.2
Altman-Z -10.48
F-Score2
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)125.54%
Cap/Depr(5y)76.05%
Cap/Sales(3y)1788.63%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.53%
EPS Next Y9.9%
EPS Next 2Y-0.78%
EPS Next 3Y0.04%
EPS Next 5Y23.58%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y1828.68%
Revenue Next 5Y730.34%
EBIT growth 1Y-15.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-53.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.51%
OCF growth 3YN/A
OCF growth 5YN/A

GENELUX CORP / GNLX FAQ

Can you provide the ChartMill fundamental rating for GENELUX CORP?

ChartMill assigns a fundamental rating of 2 / 10 to GNLX.


Can you provide the valuation status for GENELUX CORP?

ChartMill assigns a valuation rating of 0 / 10 to GENELUX CORP (GNLX). This can be considered as Overvalued.


What is the profitability of GNLX stock?

GENELUX CORP (GNLX) has a profitability rating of 0 / 10.